Cynata Therapeutics to provide status of stem cell product manufacturing technology

2015-02-16 09:38:39

(MENAFN- ProactiveInvestors)

Cynata Therapeutics (ASX:CYP) has been granted an ASX trading halt regarding the status of its Cymerus™ mesenchymal stem cell product manufacture.

The halt will last until the earlier of the announcement being made or the start of trade on Thursday 19th February 2015.

Its Cymerus™ technology enables large scale production of mesenchymal stem cells from a single one-time donor – a pivotal requirement for pharmaceutical companies moving into stem cell medicine.

Earlier this month it partner with the University of Western Australia to test its stem cells in lung fibrosis disease model.

Proactive Investors Australia is the market leader in producing news articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia UK North America and Hong Kong / China.

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.